0.4752
price up icon22.16%   0.0862
after-market Handel nachbörslich: .44 -0.0352 -7.41%
loading
Schlusskurs vom Vortag:
$0.389
Offen:
$0.3745
24-Stunden-Volumen:
6.17M
Relative Volume:
15.13
Marktkapitalisierung:
$8.74M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-16.26M
KGV:
-0.4022
EPS:
-1.1814
Netto-Cashflow:
$-13.50M
1W Leistung:
+49.58%
1M Leistung:
-20.85%
6M Leistung:
-83.76%
1J Leistung:
-90.38%
1-Tages-Spanne:
Value
$0.3629
$0.5274
1-Wochen-Bereich:
Value
$0.2942
$0.5274
52-Wochen-Spanne:
Value
$0.29
$5.10

Intensity Therapeutics Inc Stock (INTS) Company Profile

Name
Firmenname
Intensity Therapeutics Inc
Name
Telefon
203-221-7381
Name
Adresse
1 ENTERPRISE DRIVE, SUITE 430, SHELTON
Name
Mitarbeiter
16
Name
Twitter
Name
Nächster Verdiensttermin
Name
Neueste SEC-Einreichungen
Name
INTS's Discussions on Twitter

Vergleichen Sie INTS mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
INTS
Intensity Therapeutics Inc
0.4752 5.85M 0 -16.26M -13.50M -1.1814
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.58 26.10B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
442.05 111.96B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.35 42.96M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
81.20 6.39B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
490.28 63.52B 14.09B 4.50B 2.96B 39.28

Intensity Therapeutics Inc Aktie (INTS) Neueste Nachrichten

pulisher
May 29, 2025

Intensity Therapeutics, Inc.'s Phase 3 INVINCIBLE-3 Sarcoma Study Selected for Presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting - PR Newswire

May 29, 2025
pulisher
May 28, 2025

Intratumoral Cancer Treatment Market 2034: EMA, PDMA, FDA - openPR.com

May 28, 2025
pulisher
May 28, 2025

Intensity Therapeutics to Collaborate with Author, Model, Executive Producer, Speaker and Breast Cancer Survivor Christine Handy - marketscreener.com

May 28, 2025
pulisher
May 28, 2025

Breast Cancer Breakthrough: Award-Winning Author Christine Handy Joins Forces With Novel Cancer Drug Developer - Stock Titan

May 28, 2025
pulisher
May 27, 2025

Liposarcoma Clinical Trial Analysis: Key Insights into Rich - GlobeNewswire

May 27, 2025
pulisher
May 23, 2025

Imunon Stock Price, Quotes and Forecasts | NASDAQ:IMNN - Benzinga

May 23, 2025
pulisher
May 23, 2025

Intensity Therapeutics stock hits 52-week low at $0.29 By Investing.com - Investing.com Nigeria

May 23, 2025
pulisher
May 23, 2025

Intensity Therapeutics stock hits 52-week low at $0.29 - Investing.com

May 23, 2025
pulisher
May 22, 2025

Alliance Global Partners Adjusts Price Target for Intensity Therapeutics (INTS) | INTS Stock News - GuruFocus

May 22, 2025
pulisher
May 21, 2025

Benchmark maintains Speculative Buy on Intensity Therapeutics stock - Investing.com

May 21, 2025
pulisher
May 21, 2025

Benchmark maintains Speculative Buy on Intensity Therapeutics stock By Investing.com - Investing.com India

May 21, 2025
pulisher
May 20, 2025

Intensity Therapeutics Faces Nasdaq Non-Compliance Notice - TipRanks

May 20, 2025
pulisher
May 19, 2025

Soft Tissue Sarcoma Pipeline Appears Robust With 70+ Key Pharma - openPR.com

May 19, 2025
pulisher
May 19, 2025

Soft Tissue Sarcoma Pipeline Appears Robust With 70+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail

May 19, 2025
pulisher
May 19, 2025

Intra-tumoral Cancer Therapies Market to Show Tremendous Growth at a CAGR of 31.3% During the Study Period (2020-2034) | DelveInsight - Yahoo Finance

May 19, 2025
pulisher
May 19, 2025

Intensity stock rating cut to Hold by Brookline Capital - Investing.com Nigeria

May 19, 2025
pulisher
May 19, 2025

Intensity Therapeutics (INTS) Downgraded as Funding Concerns Ari - GuruFocus

May 19, 2025
pulisher
May 19, 2025

Brookline Capital Downgrades Intensity Therapeutics to Hold From Buy - marketscreener.com

May 19, 2025
pulisher
May 19, 2025

Intensity Therapeutics (INTS) Downgraded as Funding Concerns Arise | INTS Stock News - GuruFocus

May 19, 2025
pulisher
May 19, 2025

Intensity Therapeutics downgraded to Hold from Buy at Brookline - TipRanks

May 19, 2025
pulisher
May 17, 2025

Intensity Therapeutics Reports Q1 2025 Financial Results - TipRanks

May 17, 2025
pulisher
May 14, 2025

Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Me - Quantisnow

May 14, 2025
pulisher
May 14, 2025

INTS Faces Challenges Yet Advances in Key Cancer Programs | INTS Stock News - GuruFocus

May 14, 2025
pulisher
May 13, 2025

Intensity Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - Nasdaq

May 13, 2025
pulisher
May 13, 2025

Health Beat: Muscle loss and cognitive function - WFMZ.com

May 13, 2025
pulisher
May 13, 2025

International Hummus Day arrives with a surge in plant-based picks - WFMZ.com

May 13, 2025
pulisher
May 13, 2025

Curious? Healthy Brain Aging Might Depend On It - WFMZ.com

May 13, 2025
pulisher
May 12, 2025

Oropharyngeal Cancer Treatment Market Size in 7MM is expected to grow at a decent CAGR by 2032, estimates DelveInsight - Barchart.com

May 12, 2025
pulisher
May 10, 2025

Intensity Therapeutics, Inc. Announces Pricing of $3 Million Reg - GuruFocus

May 10, 2025
pulisher
May 06, 2025

Intensity Therapeutics (INTS) Expands Cancer Trial to France | I - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Intensity Therapeutics (INTS) Expands Cancer Trial to France | INTS Stock News - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Receive European Medicines Agency Authorization to Initiate Phase 2 INVINCIBLE-4 (SAKK/66/22) Study for INT230-6 in the Treatment of Presurgical Triple-Negative Breast - Yahoo Finance

May 06, 2025
pulisher
May 05, 2025

Cholangiocarcinoma Clinical Trials and Studies 2025: EMA, - openPR.com

May 05, 2025
pulisher
May 05, 2025

Cholangiocarcinoma Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - Barchart.com

May 05, 2025
pulisher
May 02, 2025

Offerings News Live Feed - Stock Titan

May 02, 2025
pulisher
May 02, 2025

Intensity Therapeutics, Inc. Announces the Closing and Full Exercise of the Over-Allotment Option from its Upsized Initial Public Offering, Raising a Total of $22.425 Million in Gross Proceeds - Barchart.com

May 02, 2025
pulisher
Apr 29, 2025

Intratumoral Cancer Therapies Market Predicted to See Upsurge - openPR.com

Apr 29, 2025
pulisher
Apr 29, 2025

Post-Trade Analysis: Intensity Therapeutics Inc (INTS) Climbs 12.57, Closing at 0.64 - DWinneX

Apr 29, 2025
pulisher
Apr 29, 2025

Daily Market Movement: Lexeo Therapeutics Inc (LXEO) Sees a -3.53 Decrease, Closing at 3.55 - DWinneX

Apr 29, 2025
pulisher
Apr 29, 2025

Closing Bell Recap: Greenlane Holdings Inc (GNLN) Ends at 0.01, Reflecting a -3.23 Downturn - DWinneX

Apr 29, 2025
pulisher
Apr 29, 2025

In the Green: TMD Energy Ltd (TMDE) Closes at 1.58, Up/Down 5.33 from Previous Day - DWinneX

Apr 29, 2025
pulisher
Apr 28, 2025

Navigating INTS’s Stock Market Maze: Ups and Downs in 2023 - investchronicle.com

Apr 28, 2025
pulisher
Apr 28, 2025

The Business Case For Buying Intensity Therapeutics Inc (NASDAQ: INTS) Stock Now - Stocksregister

Apr 28, 2025
pulisher
Apr 26, 2025

Intensity Therapeutics plunges on $2.35M public offering - MSN

Apr 26, 2025
pulisher
Apr 26, 2025

US Stock Futures Dip As Oil Prices Continue To Slide - Finimize

Apr 26, 2025
pulisher
Apr 26, 2025

Analysts Conflicted on These Healthcare Names: Regeneron (REGN), Community Health (CYH) and Integer Holdings (ITGR) - The Globe and Mail

Apr 26, 2025
pulisher
Apr 26, 2025

United States shares higher at close of trade; Dow Jones Industrial Average up 0.05% - Investing.com India

Apr 26, 2025
pulisher
Apr 25, 2025

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.05% - Investing.com

Apr 25, 2025
pulisher
Apr 25, 2025

Intensity Therapeutics sets terms for $2.35 million offering - Investing.com

Apr 25, 2025
pulisher
Apr 25, 2025

Shelton biotech eyes $2.35M public offering to fund research - Hartford Business Journal

Apr 25, 2025

Finanzdaten der Intensity Therapeutics Inc-Aktie (INTS)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$1.08
price up icon 1.89%
$30.14
price down icon 3.74%
$573.26
price down icon 1.32%
$304.56
price up icon 3.98%
$4.50
price down icon 3.02%
$490.28
price down icon 19.01%
Kapitalisierung:     |  Volumen (24h):